MiRagen appoints new chairman to its board of directors

BOULDER — MiRagen Therapeutics Inc. (Nasdaq: MGEN), a biopharmaceutical company focused on RNA-targeted therapies, has appointed a new chairman to its board of directors.

Jeff Hatfield, who has been a director since 2017, will succeed Bruce Booth, who is stepping down to pursue new investments in the Atlas Venture portfolio.

Arlene Morris, also a director, will replace Booth on the audit committee. The board will be comprised of seven directors, including six non-executive directors.

“It is exciting to step into the Chairman role at MiRagen during a time when the Company has several important milestones on the horizon,” Hatfield said in a prepared statement. “I look forward to working closely with the rest of the Board and management team to advance these programs with a pathway towards potential commercialization.”

Hatfield is a veteran in the industry and CEO of Zafgen Inc. He previously served as CEO of Vitae Pharmaceuticals until it was acquired by Allergan in 2016.

Booth will continue to be involved in the company, as MiRagen is part of the Atlas Venture portfolio.

 

BOULDER — MiRagen Therapeutics Inc. (Nasdaq: MGEN), a biopharmaceutical company focused on RNA-targeted therapies, has appointed a new chairman to its board of directors.

Jeff Hatfield, who has been a director since 2017, will succeed Bruce Booth, who is stepping down to pursue new investments in the Atlas Venture portfolio.

Arlene Morris, also a director, will replace Booth on the audit committee. The board will be comprised of seven directors, including six non-executive directors.

“It is exciting to step into the Chairman role at MiRagen during a time when the Company has several important milestones on the horizon,” Hatfield said in a prepared statement. “I look forward to working closely with the rest of the Board and management team to advance these programs with a pathway towards potential commercialization.”

Hatfield is a veteran in the industry and CEO of Zafgen Inc. He previously served as CEO of Vitae Pharmaceuticals until it was acquired by Allergan in 2016.

Booth will continue to be involved in the company, as MiRagen is part of the Atlas Venture portfolio.